Author:
Fielding Katherine L,Charalambous Salome,Stenson Amy L,Pemba Lindiwe F,Martin Des J,Wood Robin,Churchyard Gavin J,Grant Alison D
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. World Health Organization. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector, progress report, April 2007. [
http://www.who.int/hiv/mediacentre/universal_access_progress_report_en.pdf
]
2. PEPFAR five year HIV/AIDS plan. [
http://www.pepfar.gov/85811.htm
]
3. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000, 133: 21-30.
4. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997, 277: 1962-1969. 10.1001/jama.277.24.1962.
5. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Deficiency. 2002, 30: 105-110. 10.1097/00126334-200205010-00014.